" Imugene (ASX:IMU) presents key findings to leading cancer research association
Imugene (IMU) presented key findings from its HER-Vaxx immunotherapy and CF33 oncolytic virus programs at the American Association for Cancer Research’s annual meeting.
" Opyl (ASX:OPL) buys back unmarketable shares
Medical tech support provider Opyl (OPL) has completed an off-market share buy-back facility for eligible shareholders who held unmarketable parcels in the company
" Universal Biosensors (ASX:UBI) takes up supply agreement with U.S. life sciences company
Universal Biosensors (UBI) has entered an exclusive agreement with U.S.-based Lubris Biopharma for the supply of Lubricin for UBI’s diagnostic products.
" Kazia Theraputics (ASX:KZA) to present data for phase II study of paxalisib in brain cancer patients
Kazia Theraputics (KZA) has released data from its ongoing phase two study of its paxalisib candidate in glioblastoma — the most common and
" Visioneering Technologies (ASX:VTI) closes oversubscribed SPP
Medical device company Visioneering Technologies (VTI) has closed its security purchase plan after raising more than expected.
" PharmAust (ASX:PAA) receives $750k R&D rebate from ATO
Clinical-stage oncology company PharmAust (PAA) has received a research and development (R&D) rebate of just over $750,000 through the R&D Tax Incentive Scheme.